VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2021 | ANCHOR: melphalan flufenamide in R/R myeloma

Roman Hajek, MD, PhD, University Hospital Ostrava, Ostrava, Czech Republic, summarizes the Phase II ANCHOR trial (NCT03481556), which investigated melphalan flufenamide (melflufen), a peptide-drug conjugate (PDC), and dexamethasone with either bortezomib or daratumumab in patients with relapsed/refractory (R/R) multiple myeloma. In a group of pretreated patients, the optimal dose of melflufen was determined to be 30 mg and no dose-related toxicities were observed. Recruitment is currently ongoing and additional data will be presented in the future. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter